Overexpression of erbB-2 protein in gastric adenocarcinoma - A potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen

J. K. Roh, S. Paik, H. C. Chung, W. Yang, H. K. Kim, I. J. Choi, J. Kim, E. Koh, K. S. Lee, J. S. Min, J. Yoon, B. S. Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In order to study the influence of erbB-2 protein overexpression on outcome of patients with gastric cancer after attempted curative resection with or without adjuvant chemotherapy, paraffin embedded sections from 109 cases of primary gastric cancer with defined treatments have been immunostained for erbB-2 protein in a retrospective study. Thirty four cases (31%) showed strong membrane staining of tumor cells. erbB-2 overexpression did not show significant effect on outcome when all patients are considered. However, erbB-2 overexpression was an indicator for poor disease free survival (p = 0.0474), local relapse free survival (p = 0.0293), and overall survival (p = 0.0310) of the patients treated with surgery only (N = 51), while it did not show any effect on outcome of patients treated with 5-FU plus Doxorubicin (FA) as adjuvant chemotherapy (N = 58). Furthermore, the apparent therapeutic benefit from FA regimen was restricted to patients with erbB-2 positive tumors. Combined predictive value of erbB-2 and FA regimen was found to be significant in predicting local relapse in multivariate analysis (p = 0.0439). The data suggests that erbB-2 may be associated with an improved response to FA regimen and that erbB-2 should be included as a potential confounding variable in the analysis of the data from the clinical trials for gastric cancer.

Original languageEnglish
Pages (from-to)1207-1219
Number of pages13
JournalJapanese Journal of Cancer and Chemotherapy
Volume19
Issue number8
Publication statusPublished - 1992 Jan 1

Fingerprint

Fluorouracil
Doxorubicin
Stomach
Adenocarcinoma
Stomach Neoplasms
Adjuvant Chemotherapy
Proteins
Therapeutics
Recurrence
Confounding Factors (Epidemiology)
Survival
Paraffin
Disease-Free Survival
Neoplasms
Multivariate Analysis
Retrospective Studies
Clinical Trials
Staining and Labeling
Membranes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Roh, J. K. ; Paik, S. ; Chung, H. C. ; Yang, W. ; Kim, H. K. ; Choi, I. J. ; Kim, J. ; Koh, E. ; Lee, K. S. ; Min, J. S. ; Yoon, J. ; Kim, B. S. / Overexpression of erbB-2 protein in gastric adenocarcinoma - A potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. In: Japanese Journal of Cancer and Chemotherapy. 1992 ; Vol. 19, No. 8. pp. 1207-1219.
@article{de33256a151545bf8ee81252e85050b3,
title = "Overexpression of erbB-2 protein in gastric adenocarcinoma - A potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen",
abstract = "In order to study the influence of erbB-2 protein overexpression on outcome of patients with gastric cancer after attempted curative resection with or without adjuvant chemotherapy, paraffin embedded sections from 109 cases of primary gastric cancer with defined treatments have been immunostained for erbB-2 protein in a retrospective study. Thirty four cases (31{\%}) showed strong membrane staining of tumor cells. erbB-2 overexpression did not show significant effect on outcome when all patients are considered. However, erbB-2 overexpression was an indicator for poor disease free survival (p = 0.0474), local relapse free survival (p = 0.0293), and overall survival (p = 0.0310) of the patients treated with surgery only (N = 51), while it did not show any effect on outcome of patients treated with 5-FU plus Doxorubicin (FA) as adjuvant chemotherapy (N = 58). Furthermore, the apparent therapeutic benefit from FA regimen was restricted to patients with erbB-2 positive tumors. Combined predictive value of erbB-2 and FA regimen was found to be significant in predicting local relapse in multivariate analysis (p = 0.0439). The data suggests that erbB-2 may be associated with an improved response to FA regimen and that erbB-2 should be included as a potential confounding variable in the analysis of the data from the clinical trials for gastric cancer.",
author = "Roh, {J. K.} and S. Paik and Chung, {H. C.} and W. Yang and Kim, {H. K.} and Choi, {I. J.} and J. Kim and E. Koh and Lee, {K. S.} and Min, {J. S.} and J. Yoon and Kim, {B. S.}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "19",
pages = "1207--1219",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",

}

Roh, JK, Paik, S, Chung, HC, Yang, W, Kim, HK, Choi, IJ, Kim, J, Koh, E, Lee, KS, Min, JS, Yoon, J & Kim, BS 1992, 'Overexpression of erbB-2 protein in gastric adenocarcinoma - A potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen', Japanese Journal of Cancer and Chemotherapy, vol. 19, no. 8, pp. 1207-1219.

Overexpression of erbB-2 protein in gastric adenocarcinoma - A potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. / Roh, J. K.; Paik, S.; Chung, H. C.; Yang, W.; Kim, H. K.; Choi, I. J.; Kim, J.; Koh, E.; Lee, K. S.; Min, J. S.; Yoon, J.; Kim, B. S.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 19, No. 8, 01.01.1992, p. 1207-1219.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overexpression of erbB-2 protein in gastric adenocarcinoma - A potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen

AU - Roh, J. K.

AU - Paik, S.

AU - Chung, H. C.

AU - Yang, W.

AU - Kim, H. K.

AU - Choi, I. J.

AU - Kim, J.

AU - Koh, E.

AU - Lee, K. S.

AU - Min, J. S.

AU - Yoon, J.

AU - Kim, B. S.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - In order to study the influence of erbB-2 protein overexpression on outcome of patients with gastric cancer after attempted curative resection with or without adjuvant chemotherapy, paraffin embedded sections from 109 cases of primary gastric cancer with defined treatments have been immunostained for erbB-2 protein in a retrospective study. Thirty four cases (31%) showed strong membrane staining of tumor cells. erbB-2 overexpression did not show significant effect on outcome when all patients are considered. However, erbB-2 overexpression was an indicator for poor disease free survival (p = 0.0474), local relapse free survival (p = 0.0293), and overall survival (p = 0.0310) of the patients treated with surgery only (N = 51), while it did not show any effect on outcome of patients treated with 5-FU plus Doxorubicin (FA) as adjuvant chemotherapy (N = 58). Furthermore, the apparent therapeutic benefit from FA regimen was restricted to patients with erbB-2 positive tumors. Combined predictive value of erbB-2 and FA regimen was found to be significant in predicting local relapse in multivariate analysis (p = 0.0439). The data suggests that erbB-2 may be associated with an improved response to FA regimen and that erbB-2 should be included as a potential confounding variable in the analysis of the data from the clinical trials for gastric cancer.

AB - In order to study the influence of erbB-2 protein overexpression on outcome of patients with gastric cancer after attempted curative resection with or without adjuvant chemotherapy, paraffin embedded sections from 109 cases of primary gastric cancer with defined treatments have been immunostained for erbB-2 protein in a retrospective study. Thirty four cases (31%) showed strong membrane staining of tumor cells. erbB-2 overexpression did not show significant effect on outcome when all patients are considered. However, erbB-2 overexpression was an indicator for poor disease free survival (p = 0.0474), local relapse free survival (p = 0.0293), and overall survival (p = 0.0310) of the patients treated with surgery only (N = 51), while it did not show any effect on outcome of patients treated with 5-FU plus Doxorubicin (FA) as adjuvant chemotherapy (N = 58). Furthermore, the apparent therapeutic benefit from FA regimen was restricted to patients with erbB-2 positive tumors. Combined predictive value of erbB-2 and FA regimen was found to be significant in predicting local relapse in multivariate analysis (p = 0.0439). The data suggests that erbB-2 may be associated with an improved response to FA regimen and that erbB-2 should be included as a potential confounding variable in the analysis of the data from the clinical trials for gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026675392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026675392&partnerID=8YFLogxK

M3 - Article

C2 - 1355336

AN - SCOPUS:0026675392

VL - 19

SP - 1207

EP - 1219

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 8

ER -